Search Results

There are 5373 results for: content related to: Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists

  1. You have free access to this content
    Romiplostim in the management of the thrombocytopenic surgical patient

    Transfusion

    Volume 55, Issue 10, October 2015, Pages: 2505–2510, Ariela L. Marshall, Katayoon Goodarzi and David J. Kuter

    Version of Record online : 30 MAY 2015, DOI: 10.1111/trf.13181

  2. Use of eltrombopag after romiplostim in primary immune thrombocytopenia

    British Journal of Haematology

    Volume 169, Issue 1, April 2015, Pages: 111–116, José Ramón González-Porras, María Eva Mingot-Castellano, Marcio M. Andrade, Rafael Alonso, Isabel Caparrós, María Carmen Arratibel, Fernando Fernández-Fuertes, Maria José Cortti, Cristina Pascual, Blanca Sánchez-González, Silvia Bernat, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Pavel E. Olivera, María Teresa Alvarez-Román, Isidro Jarque, Montserrat Cortés, Violeta Martínez-Robles, Francisco Javier Díaz-Gálvez, María Calbacho, Carmen Fernández-Miñano, Javier Garcia-Frade and Tomás José González-López

    Version of Record online : 18 DEC 2014, DOI: 10.1111/bjh.13266

  3. You have free access to this content
    A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 5, May 2012, Pages: 799–806, Y. TOMIYAMA, Y. MIYAKAWA, S. OKAMOTO, S. KATSUTANI, A. KIMURA, Y. OKOSHI, H. NINOMIYA, H. KOSUGI, S. NOMURA, K. OZAKI, Y. IKEDA, T. HATTORI, K. KATSURA and Y. KANAKURA

    Version of Record online : 2 MAY 2012, DOI: 10.1111/j.1538-7836.2012.04695.x

  4. You have full text access to this OnlineOpen article
    Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study

    Cancer Medicine

    Volume 4, Issue 1, January 2015, Pages: 16–26, Eric S. Winer, Howard Safran, Boguslawa Karaszewska, Donald A. Richards, Lee Hartner, Frederic Forget, Rodryg Ramlau, Kirushna Kumar, Bhabita Mayer, Brendan M. Johnson, Conrad A. Messam and Yasser Mostafa Kamel

    Version of Record online : 27 AUG 2014, DOI: 10.1002/cam4.326

  5. You have free access to this content
    Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease

    British Journal of Clinical Pharmacology

    Volume 77, Issue 3, March 2014, Pages: 532–544, Colm Farrell, Siobhan C. Hayes, Mary Wire and Jianping Zhang

    Version of Record online : 21 FEB 2014, DOI: 10.1111/bcp.12244

  6. Effect of Hepatic or Renal Impairment on Eltrombopag Pharmacokinetics

    The Journal of Clinical Pharmacology

    Volume 51, Issue 5, May 2011, Pages: 739–750, Dr John W. Bauman, Dr Carolyn T. Vincent, Dr Bin Peng, Dr Mary B. Wire, Dr Daphne D. Williams and Dr Jung Wook Park

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010372106

  7. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection

    Clinical and Experimental Pharmacology and Physiology

    Volume 42, Issue 10, October 2015, Pages: 1030–1035, Mohammad I Saleh, Abdullah R Obeidat, Hanan A Anter and Anas A Khanfar

    Version of Record online : 15 SEP 2015, DOI: 10.1111/1440-1681.12451

  8. Pharmacokinetics and Pharmacodynamics Clinical Pharmacokinetics, Platelet Response, and Safety of Eltrombopag at Supratherapeutic Doses of up to 200 mg Once Daily in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 51, Issue 3, March 2011, Pages: 301–308, Ms Gemma Matthys, Dr Jung Wook Park, Ms Sandra McGuire, Dr Mary Beth Wire, Ms Carolyn Bowen, Dr Daphne Williams, Mr Julian Jenkins and Dr Bin Peng

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270010368677

  9. Are Risk Evaluation and Mitigation Strategies Associated With Less Off-Label Use of Medications? The Case of Immune Thrombocytopenia

    Clinical Pharmacology & Therapeutics

    Volume 97, Issue 2, February 2015, Pages: 186–193, A Sarpatwari, JM Franklin, J Avorn, JD Seeger, JE Landon and AS Kesselheim

    Version of Record online : 20 DEC 2014, DOI: 10.1002/cpt.17

  10. Population PK/PD Modeling of Eltrombopag in Healthy Volunteers and Patients With Immune Thrombocytopenic Purpura and Optimization of Response-Guided Dosing

    The Journal of Clinical Pharmacology

    Volume 51, Issue 10, October 2011, Pages: 1403–1417, Dr Siobhan Hayes, Dr Daniele Ouellet, Dr Jianping Zhang, Dr Mary B. Wire and Dr Ekaterina Gibiansky

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270010383019

  11. You have free access to this content
    Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 70, Issue 1, July 2010, Pages: 24–33, Gemma Matthys, Jung Wook Park, Sandra McGuire, Mary Beth Wire, Jianping Zhang, Carolyn Bowen, Daphne Williams, Julian M. Jenkins and Bin Peng

    Version of Record online : 24 FEB 2010, DOI: 10.1111/j.1365-2125.2010.03646.x

  12. Treatment Options for Chronic Refractory Idiopathic Thrombocytopenic Purpura in Adults: Focus on Romiplostim and Eltrombopag

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 30, Issue 7, July 2010, Pages: 666–683, Dr. Jyoti D. Chouhan and Dr. Jon D. Herrington

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.30.7.666

  13. You have free access to this content
    Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology

    Volume 90, Issue 3, March 2015, Pages: E40–E43, Tomás José González-López, Cristina Pascual, María Teresa Álvarez-Román, Fernando Fernández-Fuertes, Blanca Sánchez-González, Isabel Caparrós, Isidro Jarque, María Eva Mingot-Castellano, José Angel Hernández-Rivas, Mónica Martín-Salces, Laura Solán, Paola Beneit, Reyes Jiménez, Silvia Bernat, Marcio M. Andrade, Montserrat Cortés, Maria José Cortti, Susana Pérez-Crespo, Marta Gómez-Núñez, Pavel E. Olivera, Gloria Pérez-Rus, Violeta Martínez-Robles, Rafael Alonso, Angeles Fernández-Rodríguez, María Carmen Arratibel, María Perera, Carmen Fernández-Miñano, Miguel Angel Fuertes-Palacio, Juan Andrés Vázquez-Paganini, Isabel Gutierrez-Jomarrón, Inés Valcarce, Erik de Cabo, Adriana Sainz, Rosa Fisac, Carlos Aguilar, María Paz Martínez-Badas, María Jesús Peñarrubia, María Calbacho, Carmen de Cos, Manuel González-Silva, Erika Coria, Arancha Alonso, Alberto Casaus, Armando Luaña, Pilar Galán, Cristina Fernández-Canal, Javier Garcia-Frade and José Ramón González-Porras

    Version of Record online : 16 JAN 2015, DOI: 10.1002/ajh.23900

  14. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    British Journal of Haematology

    Volume 169, Issue 3, May 2015, Pages: 309–323, Charlotte K. Brierley and David P. Steensma

    Version of Record online : 6 FEB 2015, DOI: 10.1111/bjh.13285

  15. You have free access to this content
    Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP)

    British Journal of Haematology

    Volume 160, Issue 4, February 2013, Pages: 538–546, James B. Bussel, Mansoor N. Saleh, Sandra Y. Vasey, Bhabita Mayer, Michael Arning and Nicole L. Stone

    Version of Record online : 24 DEC 2012, DOI: 10.1111/bjh.12169

  16. You have free access to this content
    Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study

    American Journal of Hematology

    Volume 90, Issue 7, July 2015, Pages: 598–601, Russell K. Brynes, Attilio Orazi, Dickens Theodore, Paul Burgess, Christine K. Bailey, Maung M. Thein and Kalpana K. Bakshi

    Version of Record online : 22 JUN 2015, DOI: 10.1002/ajh.24011

  17. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology

    Tomás José González-López, María Teresa Alvarez-Román, Cristina Pascual, Blanca Sánchez-González, Fernando Fernández-Fuentes, Isidro Jarque, Gloria Pérez-Rus, Susana Pérez-Crespo, Silvia Bernat, José Angel Hernández-Rivas, Marcio M. Andrade, Montserrat Cortés, Marta Gómez-Nuñez, Pavel Olivera, Violeta Martínez-Robles, Angeles Fernández-Rodríguez, Miguel Angel Fuertes-Palacio, Carmen Fernández-Miñano, Erik de Cabo, Rosa Fisac, Carlos Aguilar, Abelardo Bárez, María Jesús Peñarrubia, Luis Javier García-Frade and José Ramón González-Porras

    Version of Record online : 27 JAN 2016, DOI: 10.1111/ejh.12725

  18. You have full text access to this OnlineOpen article
    Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

    STEM CELLS

    Volume 27, Issue 2, February 2009, Pages: 424–430, Connie L. Erickson-Miller, Evelyne Delorme, Shin-Shay Tian, Christopher B. Hopson, Amy J. Landis, Elizabeth I. Valoret, Teresa S. Sellers, Jon Rosen, Stephen G. Miller, Juan I. Luengo, Kevin J. Duffy and Julian M. Jenkins

    Version of Record online : 2 FEB 2009, DOI: 10.1634/stemcells.2008-0366

  19. You have free access to this content
    Thrombocytopenia in late preterm and term neonates after perinatal asphyxia

    Transfusion

    Volume 55, Issue 1, January 2015, Pages: 187–196, Robert D. Christensen, Vickie L. Baer and Hassan M. Yaish

    Version of Record online : 1 AUG 2014, DOI: 10.1111/trf.12777

  20. You have free access to this content
    Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers

    British Journal of Clinical Pharmacology

    Volume 72, Issue 2, August 2011, Pages: 321–329, Alicia J. Allred, Carolyn J. Bowen, Jung Wook Park, Bin Peng, Daphne D. Williams, Mary Beth Wire and Edmund Lee

    Version of Record online : 11 JUL 2011, DOI: 10.1111/j.1365-2125.2011.03972.x